Clinical trial
Fenretinide in Treating Patients With Solid Tumors
NCT00003250 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003250 |
|---|---|
| Title | Fenretinide in Treating Patients With Solid Tumors |
| Official title | Phase I Evaluation of Fenretinide (NSC# 374551) |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | fenretinide |
| Enrollment | 31 |
| Start date | May 1, 1998 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 21, 2004 |
| Last update posted | Apr 11, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: